- The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study.
- The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania.
- Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL.
In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80-patient confirmatory Phase 3 clinical trial evaluating HyBryte(TM) (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (https://ibn.fm/ZeQoN).
The enrollment milestone represents a crucial step forward for the FLASH2 study, a randomized, double-blind, placebo-controlled clinical trial that builds upon the previous statistically significant Phase 3 FLASH study. What makes this announcement particularly noteworthy is not merely that the company has…
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
